Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Guidance Emphasizes Randomized, Blinded Trials For PMAs

This article was originally published in The Gray Sheet

Executive Summary

Clinical studies in support of pre-market approval applications should ideally be randomized and blinded, FDA maintains in recent guidance.

You may also be interested in...



FDA Articulates Design Principles For Pivotal Trials In Final Guidance

The agency prefers device pivotal trials to be randomized, double-blinded and controlled, but understands that this is “neither feasible nor practical” for some devices, according to a Nov. 7 final guidance.

A Long, Strange Trip: 510(k) Reform At One Year

A rundown by “The Gray Sheet” of the most significant 510(k) reform actions taken in 2011, what’s on deck for 2012 and what reform will mean to device makers in the near term.

Regulatory News In Brief

Regulatory news includes new bills in the Senate, CDRH pact with LifeScience Alley and more.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT030457

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel